ArticleChemical science2020
Ligand-centred redox activation of inert organoiridium anticancer catalysts.
Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 61 citations in OpenAlex.
- A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanistic Exploration of Half-Sandwich Iridium(III) Anticancer Compounds through Integrated Cellular, Proteomic, and In Vivo Analyses.Journal of medicinal chemistry · 2026Article
- Nanomedical approaches to deplete intracellular glutathione in oncology.Chemical science · 2026Review
- Understanding the Modes of Action of β-Ketoiminato Iridium(III) Complexes in Cancer Cells.Inorganic chemistry · 2025Article
- Bilosomal Encapsulation of Binuclear Phosphino Ru(II)-Cu(II) Compounds Enhances Their Selectivity and Activity toward Lung and Prostate Cancers.Journal of medicinal chemistry · 2025Article
- Selective Iridium-Catalyzed Reductive Amination Inside Living Cells.Journal of the American Chemical Society · 2025Article
- Bioorthogonal Postlabeling Reveals Nuclear Localization of a Highly Cytotoxic Half-Sandwich Ir(III) Tetrazine Complex in Live Cells.Chembiochem : a European journal of chemical biology · 2025Article
- Taming glutathione potentiates metallodrug action.Current opinion in chemical biology · 2022Review
- Anticancer Water-Soluble Organoruthenium Complexes: Synthesis and Preclinical Evaluation.Chembiochem : a European journal of chemical biology · 2022Article
- Current status of iridium-based complexes against lung cancer.Frontiers in pharmacology · 2022Review
- Osmium(ii) tethered half-sandwich complexes: pH-dependent aqueous speciation and transfer hydrogenation in cells.Chemical science · 2021Article
- A Comparative Analysis of the In Vitro Anticancer Activity of Iridium(III) {ηInternational journal of molecular sciences · 2021Article
- Metallodrugs are unique: opportunities and challenges of discovery and development.Chemical science · 2020Review
- Synthesis, Characterisation and In Vitro Anticancer Activity of Catalytically Active Indole-Based Half-Sandwich Complexes.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organometallic complexes with novel activation mechanisms are attractive anticancer drug candidates. Here, we show that half-sandwich iodido cyclopentadienyl iridium(iii) azopyridine complexes exhibit potent antiproliferative activity towards cancer cells, in most cases more potent than cisplatin. Despite their inertness towards aquation, these iodido complexes can undergo redox activation by attack of the abundant intracellular tripeptide glutathione (GSH) on the chelated azopyridine ligand to generate paramagnetic intermediates, and hydroxyl radicals, together with thiolate-bridged dinuclear iridium complexes, and liberate reduced hydrazopyridine ligand. DFT calculations provided insight into the mechanism of this activation. GS
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.